SARS‐CoV‐2 research using human pluripotent stem cells and organoids

Sayaka Deguchi, Ángel Serrano‐aroca, Murtaza M. Tambuwala, Bruce D. Uhal, Adam M. Brufsky, Kazuo Takayama

Research output: Contribution to journalArticlepeer-review

2 Downloads (Pure)


Experimental cell models are indispensable for clarifying the pathophysiology of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and for developing therapeutic agents. To recapitulate the symptoms and drug response of COVID-19 patients in vitro, SARS-CoV-2 studies using physiologically relevant human embryonic stem (ES)/induced pluripotent stem (iPS) cell-derived somatic cells and organoids are ongoing. These cells and organoids have been used to show that SARS-CoV-2 can infect and damage various organs including the lung, heart, brain, intestinal tract, kidney, and pancreas. They are also being used to develop COVID-19 therapeutic agents, including evaluation of their antiviral efficacy and safety. The relationship between COVID-19 aggravation and human genetic backgrounds has been investigated using genetically modified ES/iPS cells and patient-derived iPS cells. This review summarizes the latest results and issues of SARS-CoV-2 research using human ES/iPS cell-derived somatic cells and organoids.
Original languageEnglish
Number of pages9
JournalSTEM CELLS Translational Medicine
Publication statusPublished - 24 Jul 2021


Dive into the research topics of 'SARS‐CoV‐2 research using human pluripotent stem cells and organoids'. Together they form a unique fingerprint.

Cite this